2023 journal article

Cite it

Comparative growth dynamics of bacterial and fungal contaminants in bupivacaine liposomal injectable suspension, bupivacaine 0.5%, and propofol

PLOS ONE, 18(2).

By: A. Wallace ⁿ, L. Love ⁿ, C. Gensler ⁿ, M. Jacob ⁿ, J. Robertson ⁿ  & K. Messenger ⁿ

MeSH headings : Propofol / pharmacology; Bupivacaine / pharmacology; Prospective Studies; Anesthetics; Escherichia coli; Anesthetics, Local / pharmacology

TL;DR: Bacterial and fungal contaminant growth in artificially inoculated BLIS is organism dependent and extra-label handling of BLIS should only be undertaken with caution and with adherence to strict aseptic technique. (via Semantic Scholar)

10.1371/journal.pone.0281768

Find Text @ NCSU

journals.plos.org (publisher PDF)

PubMed

UN Sustainable Development Goal Categories

3. Good Health and Well-being (Web of Science)

Source: Web Of Science

Added: August 28, 2023

Objective To determine whether bupivacaine liposomal injectable suspension (BLIS) supports microbial growth when artificially inoculated and to evaluate liposomal stability in the face of this extrinsic contamination as evidenced by changes in free bupivacaine concentrations.